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46 The Journal of Thoracic and Cardiobjectives: Pretreatment staging of patients with non–small cell lung cancer is
ritically important in determining an appropriate treatment plan. As positron
mission tomography (PET) and computed tomography (CT) are proven comple-
entary modalities in clinical staging, recent advances in PET technology have
rought forth integrated PET/CT as the new standard. We tested the hypothesis that
mprovements in PET technology have not increased the sensitivity or specificity of
ET in the staging of non–small cell lung cancer to an extent that surgical staging
s no longer required.
ethods: This is a retrospective, single-institution review of 336 patients from 1995
o 2005 with biopsy-proven non–small cell lung cancer who underwent [18F]
uoro-2-deoxy-D-glucose–PET before mediastinal lymph node sampling by cervical
ediastinoscopy or thoracotomy. Clinical records, histopathologic reports, and PET
ndings were reviewed. Data were analyzed by the Pearson 2 test.
esults: Within the study population, 210 patients had routine PET and 126 had
ntegrated PET/CT. For detecting mediastinal metastases the sensitivities of PET
ersus integrated PET/CT were 61.1% versus 85.7% (P  .05), specificities were
4.3% versus 80.6% (P  .001), positive predictive values were 68.8% versus
5.8%, negative predictive values were 92.1% versus 95.2%, and overall accuracy
as 88.6% versus 81.7%.
onclusions: Improvements in PET technology have increased integrated PET/CT
ensitivity at the cost of significantly decreased specificity. Although it may appear
hat integrated PET/CT incurs fewer false negative results, the dramatic increase in
alse positive results reinforces the notion that integrated PET/CT should be used
nly as an adjunct to clinical staging and that surgical staging remains the gold
tandard in non–small cell lung cancer.
on–small cell lung cancer (NSCLC) remains the leading cause of cancer
death in the United States today.1 Given the recent advances in therapeutic
options and the changing treatment algorithms, accurate pretreatment stag-
ng in NSCLC is of paramount importance in formulating an appropriate treatment
lan. Patients without mediastinal lymph node disease (N0 or N1) have a better
rognosis and have traditionally been treated with surgical resection alone.2 Recent
vidence has demonstrated a modest improvement in survival with the addition of
djuvant chemotherapy for patients with stage II or IIIA disease.3,4 On the other
and, patients with gross mediastinal disease (N2 or N3) are commonly treated with
efinitive chemoradiotherapy.5,6
Whole-body positron emission tomography (PET) with [18F] fluoro-2-deoxy-D-
lucose (FDG) has rapidly become accepted as the standard noninvasive modality
or staging in patients with NSCLC.7-11 Although PET has been shown to be
vascular Surgery ● March 2007
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TSuperior to computed tomography (CT) for staging of
SCLC, in reality PET and CT are complementary modal-
ties whose combined diagnostic value is superior to either
tudy alone.12 Accordingly, technologic advances have in-
roduced integrated PET/CT as the newest modality in the
rmamentarium of cancer staging.
Given the novelty of PET/CT, the number of studies
omparing PET and PET/CT in NSCLC are limited, but
rowing. Recent studies have documented superior accu-
acy with integrated PET/CT over PET alone in overall
taging and diagnosis of NSCLC.13-15 However, these stud-
es have also introduced controversy as to whether PET/CT
s superior to PET for nodal staging of the mediastinum.
ecause of a greater than 95% negative predictive value,
urrent practice accepts a negative PET result without the
eed for surgical confirmation.9 By contrast, a positive PET
can requires surgical confirmation because of the high false
ositive rate from coexistent inflammatory or infectious
rocesses.16-18 Practically, however, it is not infrequent that
atients are treated with neoadjuvant therapy for suspected
2 disease or definitive chemoradiotherapy for N3 disease
olely on the basis of a positive PET result. Previous studies
howed that surgical staging was still required because of a
elatively high false positive rate with PET in mediastinal
taging.16-18 We contend that integrated PET/CT also has
ot improved specificity to replace surgical staging as the
ole diagnostic tool in NSCLC. Accordingly, the purpose of
his study was to review our experience and compare the
iagnostic accuracy between PET and integrated PET/CT
or nodal staging in NSCLC.
atients and Methods
atient Selection
retrospective review was performed on all patients who under-
ent surgical mediastinal lymph node biopsy by cervical medias-
inoscopy, anterior mediastinotomy, thoracotomy or a combination
f these methods, between January 1995 and December 2005 on
he Thoracic Surgery Service at the University of California, Davis
ancer Center. Only newly diagnosed patients with biopsy-proven
SCLC and preoperative staging PET scans were included. Pa-
ients were segregated into two study groups: standard PET versus
imultaneously acquired integrated PET/CT. The PET scans were
Abbreviations and Acronyms
CI  confidence interval
CT  computed tomography
FDG  [18F] fluoro-2-deoxy-D-glucose
NS  not significant
NSCLC non–small cell lung cancer
PET  positron emission tomography
SUV  standard uptake valuehen compared with the reference standard of pathologic results to C
The Journal of Thoracicetermine sensitivity, specificity, positive and negative predictive
alues, and accuracy. This study was approved by the Institutional
eview Board at the University of California at Davis Medical
enter.
ET and Integrated PET/CT Imaging
ll PET studies were performed after patient fasting for a mini-
um of 4 hours. PET images were obtained with a dedicated PET
ystem (ECAT EXACT 921; CTI, Knoxville, Tenn). PET/CT
mages were obtained with an integrated PET/CT scanner (Dis-
overy LS; GE Medical Systems, Waukesha, Wis; or ECAT Re-
eal XVI; CTI, Knoxville, Tenn). Whole-body scans were ob-
ained 30 to 60 minutes after intravenous injection of 10 to 20 mCi
f FDG. For PET imaging, projection and tomographic images in
he axial, coronal, and sagittal planes were reconstructed both with
nd without attenuation correction. For PET/CT imaging, simul-
aneously acquired CT data were used for attenuation correction.
ll studies were read by dedicated nuclear medicine physicians
ith a specialty in interpreting PET scan images. Clinical histories
nd pertinent CT scans were available for review. Intraobserver
ariability was not assessed. Mediastinal lymph nodes were read as
ositive if their activity was definitely above the surrounding
ediastinal activity and not according to standard uptake values
SUV). Only patients with ipsilateral (N2) or contralateral (N3)
ediastinal disease were considered to have positive results for
his study.
ediastinal Lymph Node Staging
xtended mediastinal lymph node staging was completed in all
atients by cervical mediastinoscopy, anterior mediastinotomy, or
horacotomy. In patients with normal mediastinoscopy results,
horacotomy followed typically within 14 days. The results of PET
nd CT scanning were available to the surgeon at the time of
esection. All visible and technically feasible lymph nodes were
emoved and were annotated according to the revised International
taging System.19,20 Pathologic reports were reviewed to deter-
ine whether any mediastinal lymph nodes contained cancer. Only
atients with pathologic disease in lymph nodes that would have
een accessible by mediastinoscopy (stations 2, 4, and 7), medi-
stinotomy (stations 5 and 6), right thoracotomy (stations 2, 4, 7,
nd 9), or left thoracotomy (stations 4, 5, 6, and 9) were considered
ositive in this study. There were no changes in surgical routine
uring the study period.
tatistics
athologic findings served as the “gold standard.” Sensitivity,
pecificity, positive predictive value, negative predictive value,
nd accuracy were calculated at the patient level. Exact bino-
ial confidence intervals were determined for each. Compari-
ons between PET and PET/CT diagnostic test characteristics
ere made with the 2 test for independent groups. Differences
etween the groups on demographic and baseline characteristics
ere assessed by the 2 or t test. Statistical analysis was carried
ut with SAS version 9.1 for Windows (SAS Institute, Inc,
ary, NC).
and Cardiovascular Surgery ● Volume 133, Number 3 747
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TSesults
etween January 1995 and December 2005 at the Univer-
ity of California, Davis Cancer Center, 629 patients under-
ent surgical mediastinal lymph node biopsy with an aver-
ge of 4 lymph node stations sampled. Of the 293 patients
xcluded from this study, 269 did not have pathologic
iagnosis of NSCLC, 16 patients did not have a preproce-
ure PET scan, 5 patients had previous staging procedures,
nd 3 patients did not have lymph node tissue on biopsy.
The remaining 336 patients were segregated into stan-
ard PET (n  210) and PET/CT (n  126). Table 1 shows
he population demographics of the two patient groups. The
tandard PET group had 44% men and 56% women with a
ean age of 65.1 years (range 32-86 years). The PET/CT
roup had 42% men and 58% women with a mean age of 67
ears (range 37-86 years). The accuracy of mediastinoscopy
n the PET group compared with the PET/CT group was
8% (50/51) and 97.7% (43/44), respectively (data not
hown).
The prevalence of mediastinal metastases by surgical
taging was 17.1% (36/210) in the PET group compared
ith 22.2% (28/126) in the PET/CT group (P  not signif-
cant [NS]). For detecting mediastinal metastases the sensi-
ivities of standard PET versus PET/CT were 61.1% versus
5.7% (P  .05); specificities were 94.3% versus 80.6%
P  .001); positive predictive values were 68.8% versus
5.8% (P  NS); negative predictive values were 92.1%
ersus 95.2% (P  NS); and overall accuracy was 88.6%
ersus 81.7% (P  NS) (Tables 2 to 4).
There were 4.8% (10/310, 95% confidence interval [CI]
ABLE 1. Baseline patient characteristics
haracteristic
Standard PET
(n  210)
Integrated PET/CT
(n  126) P value
ge (y)
Mean 65 67 .11*
Range 32-86 37-86
ale sex (%) 44 42 .69†
2/N3 mediastinal
isease (%)
17 22 .25†
rimary tumor
ocation (%)
.92†
RUL 40 41
RML 5 3
RLL 18 18
LUL 27 29
LLL 11 9
ET, Positron emission tomography; CT, computed tomography; RUL, right
pper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper
obe; LLL, left lower lobe. There were no differences between groups with
espect to age, sex, incidence of mediastinal disease, or location of
rimary tumor. *P value for pooled t test. †P value for 2 test..3%-8.6%) false positive results in the PET group com- C
48 The Journal of Thoracic and Cardiovascular Surgery ● Marcared with 15.1% (19/126, 95% CI 9.3%-22.5%) in the
ET/CT group. Within the PET group, 8 of 10 patients had
oexistent inflammatory or infectious etiologies. One pa-
ient may have had a sampling error inasmuch as the me-
iastinoscopy results were negative, but the patient was
ound to have stage IV disease at thoracotomy. One patient
as believed to have an incorrect interpretation of primary
umor activity adjacent to the mediastinum. Within the
ET/CT group, 17 of 19 patients had coexistent inflamma-
ory, neoplastic, or infectious etiologies. Two patients had
o identifiable coexistent pathologic processes.
Fifty-one (24%) of 210 patients in the PET group and 44
35%) of 126 patients in the PET/CT group underwent a
ediastinoscopy followed by thoracotomy owing to node-
egative disease (Table 5). The indications for mediastinos-
opy in the PET versus the integrated PET/CT subgroups
ere a false positive PET scan (10/51, 20%, vs 19/44, 43%),
false positive CT (27/51, 53%, vs 22/44, 50%), or sug-
estion of either N1 disease or tumor proximity to the
ediastinum (22/51, 43%, vs 17/44, 39%), respectively
P  .01) (Table 6).
PET/CT had a false negative rate of 4.8% (4/83) when
ompared with PET (7.9%, 14/178). The 4 patients with
alse negative results in the PET/CT group had metastatic
isease on standard pathologic evaluation and thus did not
ave micrometastatic disease on histopathologic examina-
ion nor did they lack significant uptake in their primary
umors or mistaken evidence of N1 disease on PET/CT.
hree of the primary tumors were clinically and patholog-
cally T1 and the other was T2. The average length of time
rom PET/CT to resection was 33.8 days.
iscussion
ur results indicate that integrated PET/CT has not im-
roved the overall accuracy of mediastinal staging in
ABLE 2. Contingency table for PET scans in detecting
ediastinal metastases in NSCLC
Mediastinal metastasis () Mediastinal metastasis ()
ET () 22 10
ET () 14 164
ET, Positron emission tomography; NSCLC, non–small cell lung cancer.
ABLE 3. Contingency table for PET/CT scans in detecting
ediastinal metastases in NSCLC
Mediastinal metastasis () Mediastinal metastasis ()
ET () 24 19
ET () 4 79
ET, Positron emission tomography; NSCLC, non–small cell lung cancer;
T, computed tomography.
h 2007
N
i
t
i
n
s
t
w
i
i
u
t
f
8
t
c
u
w
f
m
l
i
v
e
N
i
l
P
s
o
P
r
o
r
c
s
r
m
i
m
h
w
d
t
o
s
w
c
m
g
i
s
p
C
m
s
g
t
c
T
P
S
S
P
N
A
P
d
T
M
M
T
P

T
f
C
F
F
P
P
c
a
P
h
Lee et al General Thoracic Surgery
G
TSSCLC over standard PET imaging. Improved sensitivity
n the detection of N2/N3 disease with PET/CT has come at
he cost of significantly worsened specificity. The drastic
ncrease in false positive results reinforces the continued
eed for surgical staging in the treatment of NSCLC.
FDG-PET imaging is the most accurate noninvasive
taging modality for NSCLC available today.9,21 By using
he higher rate of glycolysis in malignant cells compared
ith normal surrounding tissues, FDG-PET allows a phys-
ologic assessment of tumor activity.22 Despite the high
ncidence of false positive results, meta-analysis of PET
tility in mediastinal staging has produced a pooled sensi-
ivity of 84% and a specificity of 89%, which compares
avorably with CT (sensitivity of 57% and specificity of
2%).9 Although superior, the inherent limitations in ana-
omic precision of PET imaging have led to the evolution of
ombining PET imaging with CT scanning. Initial efforts
sing computer software to create fusion images were met
ith alignment difficulties from using images taken at dif-
erent time points.23,24 The advent of integrated PET/CT has
ade simultaneous image acquisition possible, thus ame-
iorating the problem.
Many studies have indicated the overall superiority of
ntegrated PET/CT over CT alone,25 PET alone,13-15 and
isually corrected or fused PET/CT15,26,27 in NSCLC. How-
ver, with regard to nodal staging of the mediastinum in
ABLE 4. Efficacy of mediastinal staging by PET versus
ET/CT
Standard PET
(n  210)
Integrated PET/CT
(n  126) P value*
ensitivity (%, 95% CI) 61.1 (43.5-76.9) 85.7 (67.3-96.0) .0299
pecificity (%, 95% CI) 94.3 (89.7-97.2) 80.6 (71.4-87.9) .0005
ositive predictive
value (%, 95% CI)
68.8 (50.0-83.9) 55.8 (39.9-70.9) .2552
egative predictive
value (%, 95% CI)
92.1 (87.2-95.6) 95.2 (88.1-98.7) .3658
ccuracy (%, 95% CI) 88.6 (87.2-95.6) 81.7 (88.1-98.7) .0808
ET, Positron emission tomography; CT, computed tomography. CI, confi-
ence interval. *P value for 2 test.
ABLE 5. Analysis of operations performed
Standard PET
(n  210)
Integrated PET/CT
(n  126)
ediastinoscopy or
mediastinotomy (No., %)
33 (16) 25 (20)
ediastinoscopy followed by
thoracotomy (No. %)
51 (24) 44 (35)
horacotomy (No. %) 126 (60) 57 (45)
ET, Positron emission tomography; CT, computed tomography. P value for
v2 test  .029.
The Journal of ThoracicSCLC, there does not appear to be a consensus agreement
n the utility of integrated PET/CT. A review of the recent
iterature reveals that most studies comparing PET/CT with
ET do not reach statistical significance with respect to
ensitivity or specificity because of small sample size. In
ne of the larger series, Cerfolio and associates14 compared
ET/CT with PET and showed an overall increased accu-
acy in both T and N staging. However, in the identification
f N2 disease, increased accuracy (96% vs 93%) was a
esult of improved sensitivity (69% vs 62%) and came at the
ost of worsened specificity (94% vs 97%), which is partly
upported by our results.
Logically, this makes sense. Increased sensitivity is the
esult of identifying subtle lesions smaller than 2 cm, which
ay have been lost in the background with standard PET
maging. These lesions are now visually correlated and
ore easily identified with the aid of CT imaging. This,
owever, has not resolved the established difficulty of PET
ith false positive results from inflammatory or infectious
iseases.28,29
What is even more interesting was the significant impact
he increased false positive results had on the types of
perations performed. The PET and PET/CT groups had
ignificantly different proportions of operations performed,
hich were primarily manifested by a higher rate of thora-
otomy in the PET group compared with a higher rate of
ediastinoscopy followed by thoracotomy in the PET/CT
roup. This disparity appears to be due to a significantly
ncreased number of patients with false positive PET/CT
cans, who, after a negative mediastinoscopy are able to
roceed to thoracotomy. In contrast, neither a false positive
T scan, presence of N1 disease, nor tumor proximity to the
ediastinum resulted in any significant difference. This
triking observation highlights the increased need for sur-
ical confirmation of a positive integrated PET/CT scan as
his will allow a significant number of patients to proceed to
urative resection rather than being subjected to neoadju-
ABLE 6. Analysis of patients undergoing mediastinoscopy
ollowed by thoracotomy
haracteristic
Standard PET
(n  51)
Integrated PET/CT
(n  44) P value*
alse positive PET or
PET/CT (No., %)
10 (20) 19 (43) .003
alse positive CT (No., %) 27 (53) 22 (50) .775
roximity or N1 disease
(No., %)
22 (43) 17 (39) .796
ET, Positron emission tomography; CT, computed tomography. A signifi-
antly increased number of patients were able to proceed to thoracotomy
fter a node negative mediastinoscopy owing to a false positive integrated
ET/CT scan. Also, the percentages do not total 100% as some patients
ad multiple indications for mediastinoscopy. *P value for 2 test.ant or definitive chemoradiation therapy.
and Cardiovascular Surgery ● Volume 133, Number 3 749
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G
TSThis study also affirms that integrated PET/CT maintains
low false negative rate and is sufficient evidence to rule
ut mediastinal spread. Recent evidence has suggested that
2 tumors are more likely to harbor occult N2 disease in
atients with clinical stage I disease.30 However, owing to a
imited sample size, this study was not able to affirm or deny
hose findings. Thus, although the spatial resolution with
ntegrated PET/CT is much improved from standard PET,
etection of subcentimeter lymph nodes may still pose an
bstacle in ruling out metastatic disease.
Finally, the future of pretreatment staging in NSCLC is
apidly changing. As recent trials using adjuvant platinum-
ased chemotherapy in patients with early-stage NSCLC
ave shown significantly improved survival,3,4 trials are
ow investigating the use of similar therapy in the neoad-
uvant setting. The real impact of this will be felt in the
ncreased need to more accurately stage the disease before
herapy. Although not addressed in this study, PET/CT has
een shown to be more accurate in segregating patients with
0 versus N1 disease.14 However, the high false positive
ate in PET/CT will still mandate confirmation of N1 dis-
ase. Emerging invasive technologies, such as the use of
ne needle aspiration with endoscopic ultrasound and en-
obronchial ultrasound are still being evaluated and may
ave significant benefit in confirming N1 disease. Sugges-
ion has even been made that these technologies will sup-
lant the utility of mediastinoscopy in the future.31,32 More
ikely, however, will be the future development of multi-
odality staging algorithms to address the changing treat-
ent algorithms in NSCLC. Until then, the current evidence
till supports the continued use of mediastinoscopy as the
old standard for confirmation of mediastinal disease in
SCLC.33
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iscussion
r John D. Mitchell (Denver, Colo). This study details your
nstitution’s experience with PET and subsequently PET/CT for
taging the mediastinum in the setting of NSCLC. Using integrated
ET/CT, you found improved sensitivity but reduced specificity in
etecting N2 disease. The negative predictive value remained high,
reater than 95%, and the overall accuracy of the imaging test
eclined somewhat with PET/CT to 82%. On the basis of the
ncreased false positive rate you saw with PET/CT, you advocate
or the continued need for mediastinoscopy to best stage the
ediastinal extent of disease. I agree with the ongoing need for
urgical staging in the mediastinum, and I have a few questions for
ou.
First, we have had some issues at our institution with our
uclear medicine physicians interpreting the CT part of the PET/
T. In your manuscript you report that dedicated nuclear medicine
olleagues read these studies. Do you believe that they have
dequate body imaging experience or have you seen similar prob-
ems at your institution? Could this account for some of the
hanges you saw between PET and PET/CT?
Dr Lee. I agree and this is actually a good point that was
rought up during our morning session. We have two centers
hat do the vast majority, greater than 95%, of our integrated
ET/CT imaging at our institution, and each center essentially
as dedicated physicians specialized in nuclear medicine read-
ng who are also specialized in body chest CT reading. At our
nstitution we do not have that detriment of a lack of expertise
n CT imaging. However, since the CT images acquired during
ET/CT are without contrast, any radiologist will have a more
ifficult time comparing those images versus a contrasted CT
can. However, most of these patients also have a previous
ontrasted CT scan, which also is used during the time of the
eading.
Dr Mitchell. Second, what constitutes a positive study at your
nstitution? In your manuscript you described a study as positive if
he degree of activity was “definitely above the surrounding me-
iastinum.” Do you use a specific SUV as a cutoff for a positive
tudy? It is going to have a tremendous effect on the sensitivity and
pecificity of the test.
Dr Lee. That is a good question that was actually discussed
his morning. At our institution, our radiologists typically will
ssign an SUV to our primary tumors but have not yet accepted
he practice of assigning SUVs to lymph nodes. It is our
ommon practice to use background uptake as a baseline level
nd designate as “positive” anything with increased SUV com-
ared with background. Because of this we probably were able
The Journal of Thoracico have an increased sensitivity. Likewise, because of this, the
pecificity is much lower, which leads to increased false posi-
ive results.
Dr Mitchell. On the basis of your results, have you thought
bout reinterpreting your data that would adjust your sensitivity
nd specificity based on the SUV value?
Dr Lee. That is something that we will probably want to go
ack and look at. Then if we can stratify on the basis of SUV we
ight be able to see exactly whether there is a cutoff. Dr Cerfolio
as identified around 5.2 as being that magic number at his
nstitution, and I know there is some variance from institution to
nstitution as well. I think that is something that we definitely will
ook forward to looking into.
Dr Mitchell. Next, the negative predictive value in your
tudy remains high, greater than 95%, with integrated PET/CT.
n the basis of your results, what do you advocate in terms of
urgical staging in the mediastinum if the PET/CT results are
egative?
Dr Lee. If the patient has a peripheral lesion that patients
hould be assumed to have, and if the PET/CT results are negative,
atients should be assumed to have a normal mediastinum and
hould proceed to direct thoracotomy and resection. Patients with
entral tumors, evidence of N1 disease, should be more closely
valuated with mediastinoscopy first. If the patients have large
ulky central lesions that may require pneumonectomy, it is to
heir benefit to clearly identify or rule them out from having
ediastinal disease before pneumonectomy.
Dr Mitchell. Finally, others have reported increased accuracy
n staging the mediastinum, as you alluded to, using an integrated
ET/CT, but your data suggest otherwise. How do you account for
he differences in the studies?
Dr Lee. We also touched on this a little bit. It has to do with
ow you assign what is a positive integrated PET/CT. If the
UV or if your way of identifying or calling a positive study is
et too low, you will have a higher number of false positive
esults. There has also been evidence that geographic differ-
nces exist. In our part of the country, we actually have a much
igher incidence of both sarcoid disease and histoplasmosis.
hat may play into the fact that we had a much higher incidence
f false positive results.
Dr Robert Cerfolio (Birmingham, Ala). First of all, con-
ratulations on your fine work. I encourage you to do these
ypes of studies and I invite you to add the max-SUV and cutoff
alues because they will completely change your data and your
esults—whether the node is positive or not. I think you need to
et the bar for the max-SUV of the lymph node and objectively
all it positive or negative and then prove whether you are right
r wrong. Although your study and our study have somewhat
ifferent conclusions, I do not think they are all that different.
hat I was hoping to see was a specific T and an N and a
pecific nodal station analysis, as we have described in several
apers. Was that included in your manuscript but left out of
our presentation for lack of time, or was that not done?
Dr Lee. That actually was not done. The reason is that our nuclear
edicine readouts are not assigned to say we have an R4 node that is
ositive. They will typically just say the mediastinum is positive.
Dr Cerfolio. I think if you are going to look at the accuracy of
and Cardiovascular Surgery ● Volume 133, Number 3 751
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TShe TNM, you have to look at the accuracy for each nodal station.
sk the nuclear radiologists what the T is and what the N is and
hich N is positive to see if they are right.
Dr Lee. I totally agree. It may be that we will have to change
ur practice at our institution to start doing that.
DOCTOR. I would encourage you to take this to the pulmonol-52 The Journal of Thoracic and Cardiovascular Surgery ● Marcgy meetings, to the medical oncology and radiation oncology
eetings, because they are reading those tests. They are bypassing
ou and are treating these patients as if they have advanced
isease. The specificity question is vital, and I would strongly
ncourage you to take this information to these people. Tissue is
he issue, and we have to tell them that.h 2007
